Novavax Inc. (Nasdaq: NVAX) will develop genetically engineered pandemic and seasonal flu vaccines for the Spanish government sending the stock price soaring 80 cents to $3.30.
Novavax To Development Genetically Engineered Vaccines
June 30, 2009 at 14:04 PM EDT
